Clinical Trials
19 trialsNCT05554406 2026-05-27
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT07012044 2026-05-27
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Recruiting
NCT05564390 2026-05-26
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04493164 2026-05-22
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03629171 2026-05-20
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06928662 2026-05-15
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT04293562 2026-05-05
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group
Phase 3 Recruiting
NCT06788756 2026-04-29
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Moleculin Biotech, Inc.
Phase 2/3 Recruiting
NCT04128748 2026-04-24
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04049539 2026-04-08
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
Ohio State University Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04282187 2026-03-16
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
University of Washington
Phase 2 Recruiting
NCT05627232 2026-03-12
Tazemetostat and Palbociclib With CPX-351for R/R AML
Thomas Jefferson University
Phase 1 Recruiting
NCT03969446 2026-03-05
Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory
City of Hope Medical Center
Phase 1 Recruiting
NCT07347171 2026-01-16
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies
Cullgen (Shanghai),Inc
Phase 1 Recruiting
NCT03661307 2026-01-12
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT04707300 2025-11-20
HTLP-ONCO
Assistance Publique - Hôpitaux de Paris
Phase 1/2 Recruiting
NCT06550713 2024-08-13
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Recruiting
NCT04905810 2024-05-29
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
University of California, Davis
Phase 2 Recruiting
NCT06046313 2024-03-05
Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting